Ignite Creation Date:
2025-12-25 @ 3:11 AM
Ignite Modification Date:
2026-04-27 @ 11:24 AM
Study NCT ID:
NCT01355705
Status:
COMPLETED
Last Update Posted:
2018-09-18
First Post:
2011-05-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Sponsor:
Michaela Liedtke
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IRB-19092
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |